BBK Worldwide Establishes In-House Distribution Center
In a joint effort with Ricoh Americas Corporation*, BBK Worldwide, Inc., announces the expansion of its production facility to include full-service, in-house distribution services, called Distribution Central. These services were developed to reduce the time-to-market for production and distribution of communications materials to the clinical research sites.
BBK is committed to making the same robust tools currently available to study sites in the United States, available to study sites throughout the world. Distribution Central complements BBK's cultural adaptation, translation and variable in-house printing capabilities.
In addition to Distribution Central, BBK will be introducing an online document management system designed specifically to track recruitment and retention materials for clinical trials. Starting in October, BBK will be taking on full responsibility for regulatory submissions globally, and managing direct distribution to study sites on an expedited basis.
Clinical trial sponsors in need of assistance with any aspect of material development–from creative concepts, to development and production, to delivery at an investigator's doorstep–can contact BBK at (617) 630-4477 or info@bbkworldwide.com.
*Ricoh Americas Corporation is the US arm of Ricoh Company, Ltd., Japan.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
